At its meeting on May 16, 2022. The Transparency Council adopted Opinion No. 76/2022 on the inclusion in reimbursement of medicines containing the active substance lacosamide in the scope of indications for use or dosage or route of administration different from those specified in the Summary of Product Characteristics.
Publication with the minutes of the Transparency Council meeting